PREP

What can we help you find?
[[thumbnail_alt_text]]
Access and adherence to pre-exposure prophylaxis is vital in eradicating the HIV epidemic in the United States.
[[thumbnail_alt_text]]
Closing these gaps in care could improve access for those worse affected by HIV in developing countries.
[[thumbnail_alt_text]]
HIV drug prices rose 34% between 2012 and 2018 and continue to climb, which experts say is a huge issue.
[[thumbnail_alt_text]]
Uptake of PrEP has been slow, particularly among at-risk individuals between 13-19 years of age ar risk for HIV infection.
[[thumbnail_alt_text]]
Pharmacy Times® interviewed James Krellenstein, co-Founder, PrEP4All Collaboration and Organizer, The COVID-19 Working Group, to discuss the development of PrEP for the COVID-19 pandemic.
[[thumbnail_alt_text]]
As we consider the implications of the COVID-19 pandemic and the release of remdesivir, ICER’s expedited evaluation raises some questions related to value-based pricing evaluations.
[[thumbnail_alt_text]]
Adverse events included self-limited nausea and diarrhea with no difference between the 2 groups.
[[thumbnail_alt_text]]
Despite the rate of HIV infection in adolescents and young adults, a study found that PrEP awareness is limited.
[[thumbnail_alt_text]]
A new report from PrEP4All Collaboration warned that current research efforts aimed at controlling the COVID-19 pandemic are missing an important area of research into PrEP.
[[thumbnail_alt_text]]
Leronlimab has been granted 2 other Fast Track designations as a combination therapy with HAART for HIV and as a treatment for metastatic triple-negative breast cancer.
 
[[thumbnail_alt_text]]
On April 24, the CDC published some considerations for clinical providers who are evaluating adolescents for treatment with PrEP.
 
[[thumbnail_alt_text]]
The study sought to determine the role of HIV related medical mistrust, and willingness to use PrEP among black women in the United States.